Patents by Inventor Luke Evnin

Luke Evnin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20180291113
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: October 27, 2017
    Publication date: October 11, 2018
    Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
  • Single chain variable fragment CD3 binding proteins
    Patent number: 10066016
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: September 4, 2018
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Pui Seto, Richard J. Austin, Luke Evnin, Jeanmarie Guenot, Bryan D. Lemon
  • METHODS OF USING BISPECIFIC CD33 AND CD3 BINDING PROTEINS
    Publication number: 20180148507
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: May 26, 2016
    Publication date: May 31, 2018
    Inventors: Luke EVNIN, Jeanmarie GUENOT, Lori KUNKEL
  • INDUCIBLE BINDING PROTEINS AND METHODS OF USE
    Publication number: 20180134789
    Abstract: Provided herein are conditionally activated polypeptide constructs comprising a protease-activated domain binding to CD3, at least one half-life extension domain, and two or more domains binding to one or more target antigens. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such polypeptide constructs. Also disclosed are methods of using the disclosed polypeptide constructs in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: October 6, 2017
    Publication date: May 17, 2018
    Inventors: Patrick BAEUERLE, Robert B. DUBRIDGE, Holger WESCHE, Luke EVNIN, Jeanmarie GUENOT, Anand PANCHAL, Maia VINOGRADOVA
  • Single domain serum albumin binding protein
    Patent number: 9920115
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: March 20, 2018
    Inventors: Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Luke Evnin, Jeanmarie Guenot
  • PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES
    Publication number: 20180057594
    Abstract: Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.
    Type: Application
    Filed: September 29, 2017
    Publication date: March 1, 2018
    Inventor: Luke EVNIN
  • SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS
    Publication number: 20170369575
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: September 14, 2017
    Publication date: December 28, 2017
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan D. LEMON
  • SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
    Publication number: 20170369563
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: September 14, 2017
    Publication date: December 28, 2017
    Inventors: Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT
  • SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS
    Publication number: 20170334997
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: May 19, 2017
    Publication date: November 23, 2017
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan D. LEMON
  • SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
    Publication number: 20170334979
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: May 19, 2017
    Publication date: November 23, 2017
    Inventors: Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 9803029
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: October 31, 2017
    Assignee: AMPHIVENA THERAPEUTICS, INC.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • TRISPECIFIC BINDING PROTEINS AND METHODS OF USE
    Publication number: 20170298149
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: June 22, 2017
    Publication date: October 19, 2017
    Inventors: Patrick BAEUERLE, Luke EVNIN, Jeanmarie GUENOT, Vanitha RAMAKRISHNAN, Holger WESCHE
  • Trispecific binding proteins and methods of use
    Patent number: 9708412
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: July 18, 2017
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Patrick Baeuerle, Luke Evnin, Jeanmarie Guenot, Vanitha Ramakrishnan, Holger Wesche
  • TRISPECIFIC BINDING PROTEINS AND METHODS OF USE
    Publication number: 20160340444
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: May 20, 2016
    Publication date: November 24, 2016
    Inventors: Patrick BAEUERLE, Luke EVNIN, Jeanmarie GUENOT, Vanitha RAMAKRISHNAN, Holger WESCHE
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20160194409
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: November 10, 2015
    Publication date: July 7, 2016
    Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20160002333
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: March 9, 2015
    Publication date: January 7, 2016
    Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 9212225
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: December 15, 2015
    Assignee: AMPHIVENA THERAPEUTICS, INC.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
    Publication number: 20060229685
    Abstract: GERD is treated through a method and apparatus of stimulating the body organ to accelerate a discharge of contents from the duodenum of the patient to thereby encourage discharge of contents from the stomach of the patient across the pyloric valve and into the duodenum.
    Type: Application
    Filed: June 9, 2006
    Publication date: October 12, 2006
    Inventors: Mark Knudson, Timothy Conrad, Luke Evnin, Katherine Tweden